Compugen (TLV:CGEN), (NASDAQ:CGEN) is a pioneering company in the realm of computational genomics, dedicated to deciphering the complexities of the human genome to develop novel therapeutics for immunotherapy. This company focuses on the discovery and development of first-in-class therapeutics for cancer and immune-related diseases, leveraging its proprietary computational discovery platform. In alignment with its scientific advancements, Compugen is actively engaged in multiple projects aimed at identifying and characterizing potential drug targets that are novel, with an overarching goal to bring innovation to treatment paradigms. As a single-market listed entity, Compugen aims to expand its pipeline of therapeutic candidates and foster collaborations that enhance its research and development capabilities, striving to achieve breakthroughs for unmet medical needs.